Released Mar 26, 2026, after the close
10-K filed Mar 26, 2026, 85 days after period end · 0001193125-26-126192
Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$12.57M$12.57M derived+24,080.8% vs Q4 2024no prior Q3 2025 on file
Net Income$31.52M$31.52M derivedN/M vs Q4 2024N/M vs Q3 2025
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived$31,405,000N/M
Operating Cash Flowderived-$8,351,000N/M
Margins · derived
Operating margin249.8%+42028.6 pt vs Q4 2024
Net margin250.7%+40419.9 pt vs Q4 2024
What the release said
The release
Same quarter
| Metric | Q4 2025dderived from reported figures | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures |
|---|---|---|---|---|
| Revenue | $12.57M | $52.00K | $223.00K | $278.00K |
| Net Income | $31.52M | -$20.89M | $51.21M | $26.79M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Spero Therapeutics, Inc. · CIK 1701108 · Engraved from SEC EDGAR